BioSpace News Archive

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2023.

Precision BioSciences, Inc. today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations.

MediPrint Ophthalmics, a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, proudly announced the appointment of Thomas Bender as a strategic advisor.

Smith+Nephew, the global medical technology company, announces full commercial availability of its AETOS Shoulder System in the US, along with 510 clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty.

Phathom Pharmaceuticals, Inc. today announced the placement of VOQUEZNA® (vonoprazan) tablets for the treatment of adults with Erosive Esophagitis, commonly referred to as Erosive GERD (gastroesophageal reflux disease), and relief of heartburn associated with Erosive Esophagitis on the Express Scripts national formularies, effective immediately.

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2023. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission.

Pasithea Therapeutics Corp. today announced the activation of four clinical trial sites in the United States.

Molecular Assemblies, Inc. today announced the addition of two industry leaders to its Commercial-Technology Advisory Board (CTAB), which includes experts in the commercialization of nucleic acid technologies and innovative life science product solutions.

Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024.

Quest Diagnostics announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States.1 Dermatologists and other providers nationwide may begin ordering the test today from Quest Diagnostics, as well as through Dermpath Diagnostics, Quest’s subspecialty pathology business.